04605nam 2200625Ia 450 991046542950332120200520144314.01-61761-864-0(CKB)2560000000067957(EBL)3017851(SSID)ssj0000411458(PQKBManifestationID)12144844(PQKBTitleCode)TC0000411458(PQKBWorkID)10355071(PQKB)10095879(MiAaPQ)EBC3017851(Au-PeEL)EBL3017851(CaPaEBR)ebr10654822(OCoLC)923653915(EXLCZ)99256000000006795720091215d2010 uy 0engurcn|||||||||txtccrAggressive breast cancer[electronic resource] /Regina H. DeFrina, editorNew York Nova Science Publishersc20101 online resource (276 p.)Cancer etiology, diagnosis and treatments seriesDescription based upon print version of record.1-60876-881-3 Includes bibliographical references and index.""AGGRESSIVE BREAST CANCER ""; ""AGGRESSIVE BREAST CANCER ""; ""CONTENTS ""; ""PREFACE""; ""RESEARCH AND REVIEW ARTICLES""; ""THE HER2 ONCOGENE IN BREAST CANCER ""; ""ABSTRACT ""; ""INTRODUCTION ""; ""HER PROTEIN RECEPTORS: SIGNAL TRANSDUCTION AND ONCOGENESIS ""; ""Intracellular Signaling Pathways ""; ""HER-Induced Cell Cycle Progression and Survival Pathways ""; ""OVER EXPRESSION OF HER2 AND THE PROGNOSIS OF INVASIVE BREAST CANCER ""; ""HER2 as A Prognostic Factor: Node-Positive Versus Node-Negative Disease""; ""HER Status and Lymphoid Infiltration """"HER2 and Progression of Early Breast Cancer Lesions to Invasive Carcinomas""""Relationship Between HER2 and Estrogen Receptor Expression ""; ""HER2 ABNORMALITIES IN OTHER TYPES OF BREAST MALIGNANCIES ""; ""HER2 ABNORMALITIES IN OTHER TYPES OF BREAST MALIGNANCIES ""; ""Evaluating HER2 in Breast Tissue ""; ""HER2 TARGETED THERAPY IN BREAST CANCER ""; ""The Role of Trastuzumab in HER2 Overexpressing Breast Cancer ""; ""The Role of Pertuzumab in HER2 Overexpressing Breast Cancer ""; ""The Role of Trastuzumab-DM1 in HER2 Overexpressing Breast Cancer """"Inhibiting Several HER Receptors: The Role of Lapatinib in HER2 Overexpressing Breast Cancer """"Circulating Serum HER2 Levels ""; ""PROPOSED RESISTANCE TO ANTI-HER2 THERAPIES ""; ""Altered Receptor-Antibody Interaction ""; ""Increased Signaling from other Receptors of the HER Family ""; ""Increased Signaling from other Receptors Activating the MAPK and PI3K Pathways ""; ""Constitutive Activation of Downstream Effectors ""; ""HER2 OVEREXPRESSION AND CHEMOTHERAPY ""; ""Anthracyclines ""; ""Taxanes ""; ""HER2 OVEREXPRESSION AND HORMONAL THERAPY """"CNS DISEASE IN HER2 OVEREXPRESSED BREAST CANCER """"CNS Metastases in Adjuvant Trials of Trastuzumab ""; ""Prognosis of CNS Metastases in HER2 Overexpressing Breast Cancer""; ""CONCLUSION ""; ""REFERENCES""; ""MULTI-DRUG RESISTANCE AS A PROBLEM CHALLENGING BREAST CANCER CHEMOTHERAPY ""; ""ABSTRACT ""; ""INTRODUCTION""; ""1) Non-Cellular MDR Mechanisms ""; ""2) Cellular MDR Mechanisms: ""; ""1. Changes in the intracellular accumulation and distribution of the drug ""; ""1a. Alteration of drug influx ""; ""1b. Alteration of drug efflux ""; ""NORMAL TISSUE DISTRIBUTION""""PHYSIOLOGICAL FUNCTIONS OF P-GP """"PHARMACOLOGICAL FUNCTIONS OF P-GP ""; ""P-GP SUBSTRATES ""; ""2. Increase in Drug Detoxification ""; ""3. Alterations of Drug Targets ""; ""4. Increase in DNA Repair Mechanism ""; ""5. Changes in Key Genes Controlling Cell Proliferation ""; ""5a. Changes in genes responsible for cell cycle control ""; ""5b. Abrogation of apoptosis ""; ""6. Micro-Environmental Stress-Mediated Resistance of Solid Tumors ""; ""7. Cancer Cell Dormancy and Resistant Cancer Stem Cells ""; ""MODULATION OF MDR PHENOTYPE """"I. Circumvention of Drug Resistance Induced by P-Gp Pump Protein ""Cancer etiology, diagnosis, and treatments.BreastCancerBreastDiseasesElectronic books.BreastCancer.BreastDiseases.616.99/449616.99/449DeFrina Regina H898149MiAaPQMiAaPQMiAaPQBOOK9910465429503321Aggressive breast cancer2006768UNINA